Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis
We present a 79-year-old male with seronegative polyarthritis (RA) and three different neoplasms of myeloid and lymphoid origin. He was treated with methotrexate (MTX) (15 mg) weekly and prednisolone (15 mg) daily for 2 years and 4 months. The development of lymphoproliferative diseases (LPDs) including various types of lymphomas is reported to be associated with the use of MTX for the treatment of RA [1, 2].
The authors would like to thank the Interdisciplinary Bank of Biomaterials and Data of the University Hospital of Würzburg and the Julius Maximilian University of Würzburg (idbw). The implementation of the ibdw has been supported by a Bundesministerium für Bildung und Forschung (Grant number FKZ: 01EY1102). Rucha Dugge is a student of the Research Training Group 2254: Heterogeneity and Evolution in Solid Tumours (HEIST) at Ulm University funded by the Deutsche Forschungsgemeinschaft.
T.F.E.B., H.K., A.R., U.L., P.M., and R.E. designed the research and analyzed and interpreted data. T.F.E.B. and R.D. wrote the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All the performed methods and experiments were in line with the guidelines of the ethics committee of the Federal General Medical Council. Informed consent was obtained from the individual included in the study.
- 4.Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL (2009) TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23(5):905–911CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Ishiyama K, Mori H, Nolte F, Hofmann WK, Miyawaki S, Sugano S, Haferlach C, Koeffler HP, Shih LY, Haferlach T, Chiba S, Nakauchi H, Miyano S, Ogawa S (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478(7367):64–69CrossRefPubMedGoogle Scholar